Posts Tagged: "LexisNexis IP"

Over the last few decades, the world has seen a range of commercially successful products. This is especially true in the pharma sector, as blockbuster drugs yield exceedingly high revenues. The main reason for the commercial success of these drugs is the fact that the underlying active ingredients are protected by patents. Hence, the drug can be sold exclusively. After…

Gone are the days when businesses made tough decisions based on anecdotes and gut feelings. Right now, decisions need to be based on data and hard facts.  The estimated total sum of data held in online storage between Google, Amazon, Microsoft and Facebook alone is an astonishing 1.2 million terabytes. Some estimates place the amount of data on the Internet…

Webinar Sponsored By: Few things in the patent world have been as contentious as software patents have been over the last decade. Once upon a time, the best, easiest, and strongest protection was available in the United States. At least since the U.S. Supreme Court’s decision in Alice v. CLS Bank in 2014 that has not been the case. And…

Webinar Sponsored By: Conventional wisdom argues that litigation is a tax on innovation, and the PTO plays a role due to high grant rates. Accordingly, it is important to know: 1.  Which patent examiners are issuing litigated patents 2.  Are examiners who are “rubber-stamping” patents issuing litigated patents at a disproportionately higher rate 3.  Are examiners with less experience issuing…

Join Gene Quinn, patent attorney and leading commentator on patent law and innovation policy, on Tuesday, September 22 at 1pm ET. Gene will host a wide-ranging conversation on the topic of COVID-19 and the race toward a coronavirus vaccine. In addition to discussing the science and FDA processes involved, we discuss intellectual property rights and more. Joining Gene will be immunization expert Dr. Jonathan Temte, a Professor at the Wisconsin School of Medicine who also serves as a member of the CDC’s Board of Scientific Counselors, and Melissa Brand, Assistant General Counsel for Intellectual Property at the Biotechnology Innovation Organization.

Conventional wisdom argues that litigation is a tax on innovation, and the PTO plays a role due to high grant rates. Accordingly, it is important to know: 1.  Which patent examiners are issuing litigated patents 2.  Are examiners who are “rubber stamping” patents issuing litigated patents at a           disproportionately higher rate 3.  Are examiners with less…

The decision to “make” or “buy” is one of, if not, the most important decisions that corporate decision makers have to make when it comes to developing ground-breaking technology. This is the decision that can set the tone of success or loss of a company in a technology race that could define the next decades of an industry. In this…

There is wide examiner variability at the USPTO, understanding this and how it affects the prosecution process and outcomes is of the utmost importance for patent practitioners. Discover the impact of the type of examiner by exploring important milestones in the life cycle of a U.S. patent application through historical trends and counter-intuitive results. In this webinar, we will quantify…

For this webinar, we have pulled together a stellar panel of presenters from the USPTO, including: Drew Hirshfeld, Commissioner for Patents Jay Kramer, Group Director Patent Operations Matthew Such, Group Director Patent Operations In this webinar, we discuss the following topics: The patent classification system overall How applications are routed to art units How applications are assigned to examiners Much…